Lack of association between DRD2 Taq1A gene polymorphism and smoking cessation therapy: A meta-analysis

International Journal of Clinical Pharmacology and Therapeutics

Volumn 53, Issue 6, 2015, Pages 415-421

  Choi, Hye Duck ^a   Shin, Wan Gyoon ^b  

^a Yeungnam University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Drd2 taq1a; Gene polymorphism; Smoking; Smoking cessation treatment

Indexed keywords

AMFEBUTAMONE; DOPAMINE 2 RECEPTOR; NICOTINE PATCH; RIMONABANT; DRD2 PROTEIN, HUMAN; NICOTINE GUM; NICOTINIC AGENT;

ALLELE; ARTICLE; COMPARATIVE STUDY; DNA POLYMORPHISM; DRD2 GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; META ANALYSIS; NICOTINE REPLACEMENT THERAPY; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME; CHI SQUARE DISTRIBUTION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; PHENOTYPE; PREVENTION AND CONTROL; PROCEDURES; PSYCHOLOGY; RECURRENT DISEASE; RISK; RISK FACTOR; TOBACCO USE DISORDER;

BUPROPION; CHI-SQUARE DISTRIBUTION; GENE FREQUENCY; HETEROZYGOTE; HOMOZYGOTE; HUMANS; NICOTINIC AGONISTS; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D2; RECURRENCE; RISK FACTORS; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 84936749779     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202214     Document Type: Article

References (30)

1. Mackay JL, Erikson M, Ross H. The tobacco atlas. In: Mackay JL (4th eds.), Atlanta, USA. The American Cancer Society, Inc.; 2013.
2. Kalamida D, Poulas K, Avramopoulou V, Fostieri E, Lagoumintzis G, Lazaridis K, Sideri A, Zouridakis M, Tzartos SJ. Muscle and neuronal nicotinic acetylcholine receptors. Structure, function and pathogenicity. FEBS J. 2007; 274: 3799-3845. CrossRef PubMed
3. Polosa R, Benowitz NL. Treatment of nicotine addiction: present therapeutic options and pipeline developments. Trends Pharmacol Sci. 2011; 32: 281-289. CrossRef PubMed
4. Stapleton JA, Sutherland G, O'Gara C. Association between dopamine transporter genotypes and smoking cessation: a meta-analysis. Addict Biol. 2007; 12: 221-226. CrossRef PubMed
5. Ton TG, Rossing MA, Bowen DJ, Srinouanprachan S, Wicklund K, Farin FM. Genetic polymorphisms in dopamine-related genes and smoking cessation in women: a prospective cohort study. Behav Brain Funct. 2007; 3: 22. CrossRef PubMed
6. David SP, Munafò MR. Genetic variation in the dopamine pathway and smoking cessation. Pharmacogenomics. 2008; 9: 1307-1321. CrossRef PubMed
7. Lerman C, Shields PG, Audrain J, Main D, Cobb B, Boyd NR, Caporaso N. The role of the serotonin transporter gene in cigarette smoking. Cancer Epidemiol Biomarkers Prev. 1998; 7: 253-255. PubMed
8. Jönsson E, Sedvall G, Brené S, Gustavsson JP, Geijer T, Terenius L, Crocq MA, Lannfelt L, Tylec A, Sokoloff P, Schwartz JC, Wiesel FA. Dopaminerelated genes and their relationships to monoamine metabolites in CSF. Biol Psychiatry. 1996; 40: 1032-1043. CrossRef PubMed
9. Jönsson EG, Nöthen MM, Grünhage F, Farde L, Nakashima Y, Propping P, Sedvall GC. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry. 1999; 4: 290-296. CrossRef PubMed
10. Vandenbergh DJ, Persico AM, Hawkins AL, Griffin CA, Li X, Jabs EW, Uhl GR. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics. 1992; 14: 1104-1106. CrossRef PubMed
11. Gelernter J, Kranzler HR, Satel SL, Rao PA. Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. Neuropsychopharmacology. 1994; 11: 195-200. CrossRef PubMed
12. O'Gara C, Stapleton J, Sutherland G, Guindalini C, Neale B, Breen G, Ball D. Dopamine transporter polymorphisms are associated with shortterm response to smoking cessation treatment. Pharmacogenet Genomics. 2007; 17: 61-67. CrossRef PubMed
13. Han DH, Joe KH, Na C, Lee YS. Effect of genetic polymorphisms on smoking cessation: a trial of bupropion in Korean male smokers. Psychiatr Genet. 2008; 18: 11-16. CrossRef PubMed
14. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17: 1-12. CrossRef PubMed
15. Cochran W. G. The combination of estimates from different experiments. Biometrics. 1954; 10: 101-129. CrossRef
16. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22: 719-748. PubMed
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177-188. CrossRef PubMed
18. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50: 1088-1101. CrossRef PubMed
19. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315: 629-634. CrossRef PubMed
20. Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk LH Jr, Pinto A, Kucharski S, Krishnan S, Niaura R, Epstein LH. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol. 2003; 22: 541-548. CrossRef PubMed
21. Johnstone EC, Yudkin PL, Hey K, Roberts SJ, Welch SJ, Murphy MF, Griffiths SE, Walton RT. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics. 2004; 14: 83-90. CrossRef PubMed
22. Swan GE, Valdes AM, Ring HZ, Khroyan TV, Jack LM, Ton CC, Curry SJ, McAfee T. Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J. 2005; 5: 21-29. CrossRef PubMed
23. David SP, Brown RA, Papandonatos GD, Kahler CW, Lloyd-Richardson EE, Munafò MR, Shields PG, Lerman C, Strong D, McCaffery J, Niaura R. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res. 2007; 9: 821-833. CrossRef PubMed
24. Munafò MR, Johnstone EC, Murphy MF, Aveyard P. Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial. Nicotine Tob Res. 2009; 11: 404-407. Cross- Ref PubMed
25. Breitling LP, Twardella D, Hoffmann MM, Witt SH, Treutlein J, Brenner H. Prospective association of dopamine-related polymorphisms with smoking cessation in general care. Pharmacogenomics. 2010; 11: 527-536. CrossRef PubMed
26. De Ruyck K, Nackaerts K, Beels L, Werbrouck J, De Volder A, Meysman M, Salhi B, Van Meerbeeck J, Thierens H. Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients. Pharmacogenomics. 2010; 11: 1053-1063. CrossRef PubMed
27. Wilcox CS, Noble EP, Oskooilar N. ANKK1/DRD2 locus variants are associated with rimonabant efficacy in aiding smoking cessation: pilot data. J Investig Med. 2011; 59: 1280-1283. PubMed
28. Munafò MR, Timpson NJ, David SP, Ebrahim S, Lawlor DA. Association of the DRD2 gene Taq1A polymorphism and smoking behavior: a metaanalysis and new data. Nicotine Tob Res. 2009; 11: 64-76. CrossRef PubMed
29. Yudkin P, Munafò M, Hey K, Roberts S, Welch S, Johnstone E, Murphy M, Griffiths S, Walton R. Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. BMJ. 2004; 328: 989-990. CrossRef PubMed
30. Colilla S, Lerman C, Shields PG, Jepson C, Rukstalis M, Berlin J, DeMichele A, Bunin G, Strom BL, Rebbeck TR. Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenet Genomics. 2005; 15: 393-398. CrossRef PubMed